TY - JOUR
T1 - Triacetyluridine (TAU) Decreases Depressive Symptoms and Increases Brain pH in Bipolar Patients
AU - Jensen, J. Eric
AU - Daniels, Melissa
AU - Haws, Charlotte
AU - Bolo, Nicolas R.
AU - Lyoo, In Kyoon
AU - Yoon, Sujung J.
AU - Cohen, Bruce M.
AU - Stoll, Andrew L.
AU - Rusche, James R.
AU - Renshaw, Perry F.
PY - 2008/6
Y1 - 2008/6
N2 - Eleven patients with bipolar depression were given doses of up to 18 g per day of triacetyluridine (TAU) over 6 weeks to test the effect of uridine on symptoms of depression via Montgomery-Asberg Depression Rating Scale (MADRS; Asberg, Montgomery, Perris, Schalling, & Sedvall, 1978) scores and on cellular bioenergetics using phosphorus magnetic resonance spectroscopic imaging (31P-MRSI). All patients and comparison participants (n = 9) completed baseline 31P-MRSI scans, and 9 patients completed posttherapy scans. The percentage changes for MADRS scores (Week 2, -23.8; Week 3, -34.9; Week 4, -42.5) and the time effects of TAU on MADRS scores (Week 2, z = -2.07, p = .039; Week 3, z = -4.28, p < .001; Week 4, z = -4.54, p < .001) may reflect TAU effects on early symptom improvement. TAU responders (patients who had a 50% or greater reduction in MADRS scores from baseline at any time) demonstrated a significant difference from nonresponders in pH changes from baseline (effect size = 150). These results suggest that TAU treatment may decrease symptoms of depression and improve mitochondrial functioning.
AB - Eleven patients with bipolar depression were given doses of up to 18 g per day of triacetyluridine (TAU) over 6 weeks to test the effect of uridine on symptoms of depression via Montgomery-Asberg Depression Rating Scale (MADRS; Asberg, Montgomery, Perris, Schalling, & Sedvall, 1978) scores and on cellular bioenergetics using phosphorus magnetic resonance spectroscopic imaging (31P-MRSI). All patients and comparison participants (n = 9) completed baseline 31P-MRSI scans, and 9 patients completed posttherapy scans. The percentage changes for MADRS scores (Week 2, -23.8; Week 3, -34.9; Week 4, -42.5) and the time effects of TAU on MADRS scores (Week 2, z = -2.07, p = .039; Week 3, z = -4.28, p < .001; Week 4, z = -4.54, p < .001) may reflect TAU effects on early symptom improvement. TAU responders (patients who had a 50% or greater reduction in MADRS scores from baseline at any time) demonstrated a significant difference from nonresponders in pH changes from baseline (effect size = 150). These results suggest that TAU treatment may decrease symptoms of depression and improve mitochondrial functioning.
KW - bipolar disorder
KW - brain
KW - hydrogen-ion concentration (pH)
KW - phosphorus magnetic resonance spectroscopy (P-MRS)
KW - triacetyluridine (TAU)
UR - https://www.scopus.com/pages/publications/44949161985
U2 - 10.1037/1064-1297.16.3.199
DO - 10.1037/1064-1297.16.3.199
M3 - Article
C2 - 18540779
AN - SCOPUS:44949161985
SN - 1064-1297
VL - 16
SP - 199
EP - 206
JO - Experimental and Clinical Psychopharmacology
JF - Experimental and Clinical Psychopharmacology
IS - 3
ER -
